SINGAPORE , Dec. 1, 2022 /PRNewswire/ -- As we look forward to the new year, Dr Ivan Puah , Medical Director at Amaris B. Clinic, who has more than 15 years of medical aesthetics and surgical body contouring experience, shares five beauty and body sculpting trends expected to take centre stage in 2023.
01. Being in a state of au naturale
The lockdown during the COVID-19 pandemic has changed how we work and, to a large extent, how we socialise. Zoom meetings became the de rigueur, and the need to look good, rejuvenated and youthful increased.
Over time as the rules were relaxed and commuting to work, international travel and non-compulsory mask-wearing became the norm again, physical meetups have unveiled another type of self-consciousness. The toll and stress of the pandemic were nonetheless apparent with skin stress in the form of, among other things, a prematurely aged appearance. This has, in turn, raised awareness and an appreciation for the au naturale appearance.
"The preferred option of subscribing to procedures that enhance an appearance that looks more natural and subtle has increased in the last two years. People want to stand out but not end up looking like someone else. This trend will continue to experience an upward trajectory in 2023," says Dr Ivan Puah , the appointed trainer for train-the-doctor in injectables by Merz and Allergan Singapore.
02. The Need For Prevention with Injectables
Ageing is an ongoing concern, and the visible stress from the pandemic emphasised it even more. There is also an interesting demographic shift of aesthetic patients regarding ageing concerns.
"More younger people are seeking treatments to prevent and slow down the signs of ageing. This proactive approach echoes the age-old adage, "prevention is better than cure." The older generation is opting for treatments to treat apparent signs of ageing. Injectables in the forms of botulinum toxins, dermal fillers and pure hyaluronic acids continue to be popular, and their demand will not wane anytime soon. Being non-invasive with zero downtime, customisable, and capable of producing immediate results are undoubtedly their strong points," says Dr Ivan Puah .
Customised treatment where injectables are combined with medical devices, which helps to deliver a more natural-looking overall result, could potentially see a rise in the take-up rate in 2023.
03. Body Sculpting & Enhancement today & tomorrow
As the world is now presented with a social catch-up opportunity, the potential of old lifestyle habits resurfacing and the tendency to overindulge is likely to be prevalent.
Dr Ivan Puah opined, "To address issues that may arise, procedures such as liposuction will continue to be at the forefront of body contouring needs. For a doctor, having a true understanding of the body's anatomy and finding the appropriate approach that fits a patient's needs is the sum of modern liposuction. Additionally, 2023 could see a rise in demand for a more natural-looking, toned, athletic physique. Where patients cannot achieve this through exercising, dieting or other methods, body contouring with liposuction will be a great help."
Where body enhancement is a concern, autologous fat grafting will be much sought after as it delivers a more natural-looking result.
Subtle tweaks that provide satisfactory results will be much more favoured even though traditional methods such as implants will continue to be around.
04. Combo Therapy for Skin Rejuvenation & Skin Firming
Extending injectables not just for facial rejuvenation but also for other multi-purposes such as tightening and hydration on the face and body looks primed to be a trend come 2023.
Certain types of fillers can be used for purposes other than creating fullness for the face. It is also effective in treating dark eye circles, smoothing wrinkles and rejuvenating the skin in the décolletage, chest and hands. It can also be used for tightening loose skin on the abdomen.
05. Men's Demand For Aesthetic & Cosmetic Improvement
Men seeking aesthetic and cosmetic improvements will be a trend in 2023. Over the years, their numbers have been increasing, and the awareness of this need among men has been widespread.
"Seeking help for issues such as gynecomastia, for example, is no longer a taboo as it is a real problem that could have significant dire consequences for men who suffer from it. The advent of "brotox" is also a clear indicator that men need aesthetic and cosmetic improvements. Self-improvement and wanting to look good were never gender-specific. The only differentiating thing is individual needs tailored to their unique skin type and body shape," explains Dr Ivan Puah .
Men today are more confident in voicing out what they need regarding appearance and admitting their shortcomings. Body sculpting, acne and aesthetic skin treatments are just some of what men realise they need because an improved appearance improves self-confidence.
Dr Ivan Puah reminds patients to look for the right doctor who is ethical, skilled and experienced to perform any treatments they are interested in. "Do not be bought by price tags. Being cheap may have an expensive outcome," he shares.
Dr. Ivan Puah is the Medical Director of Amaris B. Clinic, a medical aesthetics, sculpting and fitness clinic in Singapore . He obtained his VASER® Body Sculpting training in Colorado and Argentina . He also received training and guidance in syringe liposculpture, fat grafting and thread lift by renowned French plastic surgeon, Dr. Pierre Francois Fournier , as well as dedicated surgical training in gynecomastia surgery in San Francisco . In Singapore , Dr. Ivan Puah is accredited by the Ministry of Health to perform liposuction and serves as the Chairman of Lipo Peer Review Committee in Singapore . Dr. Ivan Puah holds a Graduate Diploma in Family Dermatology from NUS, a Graduate Diploma in Acupuncture from TCMB, and a Graduate Diploma in Sports Medicine from LKCMedicine, NTU. He is also the appointed trainer by Allergan and Merz for fellow doctors on Botulinum Toxin and Dermal Fillers. He is also the appointed training for N-Cog Thread and Picocare Laser from Venusys Medical in Singapore .
OTHER SIGNATURE AESTHETICS & SCULPTING TREATMENTS AT AMARIS B. CLINIC
Established in 2004, Amaris B. Clinic has been providing medical aesthetics and body sculpting services. Amaris B Clinic's forte lies in body sculpting - surgically removing stubborn fat pockets to sculpt and shape different areas of the body through a variety and combination of services offered. Amaris B. Clinic received recognition as the Body Sculpting Clinic of the Year in Asia Pacific in 2022, 2021, 2020, and 2019. The clinic was also awarded "2022 Gynecomastia Clinic of the Year in Asia Pacific ", and "2020 Integrated Healthcare Medical Centre of the Year in the Asia Pacific " by GlobalHealth Asia Pacific. The clinic has also bagged the Best Innovative Treatments for Dr. Ivan Puah's proprietary liposuction technique, VASER Lipo With MDC-sculpt® Lipo Technique from Daily Vanity's Spa & Hair Awards in 2022 and 2021, and Honeycombers' Love Local Awards 2021 - Editor's Choice Winner: Best Aesthetics Clinic In Singapore .
The clinic's signature treatments include:
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Mirati Therapeutics Inc (NASDAQ: MRTX) announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation. Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety pr
The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.
A for-profit California company saw windfall dividend — and patients scrambled for care, a CBS News investigation found.
Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American So
More than half of the calories consumed by Americans come from this high-risk food group, which is associated with cognitive decline, cancer and heart disease
The toxicology report reveals past cocaine, marijuana use.
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Concurrent studies expand patient enrollment and potential to build positive database … Quoin Pharmaceuticals (NASDAQ:QNRX) has strengthened its cash position and reached several milestones to continue moving its lead candidates and other assets forward. QRX003, Quoin’s investigational product for NS (Netherton syndrome), is being
(Bloomberg) -- China is set to announce a further relaxation of Covid control measures as soon as today — including allowing some infected people to home quarantine as a nationwide policy, and reining in unnecessary testing — according to people familiar with the matter, as the government continues to quickly ease its zero-tolerance strategy amid growing public discontent. Most Read from BloombergTrump Companies Are Convicted in NY Criminal Tax Fraud TrialWall Street Goes Risk Off as Bank CEOs S
Shares of Editas Medicine Inc. rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 1/2 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated. "These promising clinical results from the RUBY trial suggest clinical proof of concept for EDIT-301 and support our belief that EDIT-301 can be a clinically differentiated, one-tim